MAPT and Alzheimer disease: Indeed, the combination of amyloid-β 42 (Aβ42), total tau protein (Tau), and hyperphosphorylated tau 181 (Ptau) in CSF, currently measured for diagnosing biological AD (Jack et al., 2018), are not useful for the diagnosis of FTD, but rather to rule out AD pathology.